Breaking Finance News

Zacks Investment Research disclosed OHR Pharmaceutical Inc (NASDAQ:OHRP), boosting its stock price target to $3.25 today

Yesterday OHR Pharmaceutical Inc (NASDAQ:OHRP) traded 1.06% higher at $2.78. The company’s 50-day moving average is $2.76 and its 200-day moving average is $2.92. The last stock close price is down -1.89% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 67,216 shares of the stock were exchanged, down from an average trading volume of 72,598

In a report announced on 10/12/2016 Zacks Investment Research upped the target of OHR Pharmaceutical Inc (NASDAQ:OHRP) to $3.25 reporting a possible upside of 0.17%.

See Chart Below

OHR Pharmaceutical Inc (NASDAQ:OHRP)

OHR Pharmaceutical Inc has a 52 week low of $2.44 and a 52 week high of $6.56 The company’s market cap is currently $0.

General Information About OHR Pharmaceutical Inc (NASDAQ:OHRP)

Ohr Pharmaceutical, Inc. is a pharmaceutical company. The Company is focusing on the development of therapeutics and delivery technologies for the treatment of ocular disease. The Company's development pipeline consists of various programs and indications at various stages of development. The Company's clinical program, OHR-102 eye drops, is a therapeutic product that provides a non-invasive therapy to improve vision outcomes without requiring multiple injections per office visit. The Company focuses on OHR-102 eye drops, which is given in combination with Lucentis injections, for the treatment of retinal diseases, including wet-age-related macular degeneration (AMD), retinal vein occlusion and proliferative diabetic retinopathy. The Company's product pipeline also includes SKS Sustained Release Ocular Drug Delivery Platform Technology, Animal Model for Dry-AMD and Non-Ophthalmology Assets. OHR-102 is a small molecule anti-angiogenic drug with an intracellular mechanism of action.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *